Thread: Can-Fite on go with mid-stage study of namodenoson in fatty liver disease - Seeking Alpha
View Single Post
  #1  
Unread 07-18-2017, 07:52 AM
nmrlearner's Avatar
nmrlearner nmrlearner is offline
Senior Member
  
Join Date: Jan 2005
Posts: 23,198
Points: 193,617, Level: 100
Points: 193,617, Level: 100 Points: 193,617, Level: 100 Points: 193,617, Level: 100
Level up: 0%, 0 Points needed
Level up: 0% Level up: 0% Level up: 0%
Activity: 50.7%
Activity: 50.7% Activity: 50.7% Activity: 50.7%
Last Achievements
Award-Showcase
NMR Credits: 0
NMR Points: 0
Downloads: 0
Uploads: 0
Default Can-Fite on go with mid-stage study of namodenoson in fatty liver disease - Seeking Alpha


Can-Fite on go with mid-stage study of namodenoson in fatty liver disease
Seeking Alpha
The primary endpoint will be the percent change from baseline in liver triglyceride concentration as measured by nuclear magnetic resonance spectroscopy. Namodenoson, formerly CF102, is an orally available small molecule that binds to a protein that is ...
Can-Fite BioPharma (CANF) Says Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient ...StreetInsider.com

all 4 news articles »

Can-Fite on go with mid-stage study of namodenoson in fatty liver disease - Seeking Alpha
More...
Reply With Quote

Did you find this post helpful? Yes | No